Literature DB >> 2785508

Acidic cellular environments: activation of latent TGF-beta and sensitization of cellular responses to TGF-beta and EGF.

P Jullien1, T M Berg, D A Lawrence.   

Abstract

Transient (about 2 hr) acidification to approx. pH 5.0 of agar-gelled overlayers containing untransformed NRK-49F or KiMSV-transformed NRK-49F cells in the presence of fetal calf serum or crude 49F-cell conditioned medium, as sources of latent TGF-beta, elicited EGF-dependent colony formation of 49F cells and inhibited spontaneous growth of transformed cells. Pure, active TGF-beta (porcine, type I) had the same effects on these respective cell types, suggesting that the above results were due to activation of latent TGF-beta in the transiently acidic cellular environment. Similar acidifications in the absence of a source of latent TGF-beta enhanced the positive growth response of 49F and AKR-2B cells to EGF and active TGF-beta and also the negative growth response of KiMSV-transformed 49F cells to active TGF-beta. These results are compatible with the idea that acidic cellular environments, particularly in tumor tissues, are conducive to activation of latent TGF-beta, perhaps in conjunction with other activating mechanisms, and to an enhanced response to some growth factors. However, the heterogeneity of cell populations within tumoral masses presents an obstacle to a clear understanding of the consequences of such activation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2785508     DOI: 10.1002/ijc.2910430525

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

Review 1.  Latent-TGF-beta: an overview.

Authors:  D A Lawrence
Journal:  Mol Cell Biochem       Date:  2001-03       Impact factor: 3.396

Review 2.  The extracellular regulation of growth factor action.

Authors:  R Flaumenhaft; D B Rifkin
Journal:  Mol Biol Cell       Date:  1992-10       Impact factor: 4.138

3.  Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor.

Authors:  P A Dennis; D B Rifkin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

Review 4.  Integrin-mediated transforming growth factor-beta activation, a potential therapeutic target in fibrogenic disorders.

Authors:  Stephen L Nishimura
Journal:  Am J Pathol       Date:  2009-09-03       Impact factor: 4.307

5.  Production of autostimulatory growth factors by the human carcinoma line, RPMI 2650.

Authors:  B M Carey; M Dooley; R Weedle; M Clynes
Journal:  In Vitro Cell Dev Biol       Date:  1993-02

Review 6.  Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins.

Authors:  Ian B Robertson; Daniel B Rifkin
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-06-01       Impact factor: 10.005

7.  TGF-beta1 in Aplysia: role in long-term changes in the excitability of sensory neurons and distribution of TbetaR-II-like immunoreactivity.

Authors:  J Chin; A Angers; L J Cleary; A Eskin; J H Byrne
Journal:  Learn Mem       Date:  1999 May-Jun       Impact factor: 2.460

8.  Neutralizing antibodies against transforming growth factor beta potentiate the proliferation of Ki-1 positive lymphoma cells. Further evidence for negative autocrine regulation by transforming growth factor beta.

Authors:  S R Newcom; K K Tagra; M E Kadin
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

9.  Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine.

Authors:  P Bernasconi; E Torchiana; P Confalonieri; R Brugnoni; R Barresi; M Mora; F Cornelio; L Morandi; R Mantegazza
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

Review 10.  Unchaining the beast; insights from structural and evolutionary studies on TGFβ secretion, sequestration, and activation.

Authors:  Ian B Robertson; Daniel B Rifkin
Journal:  Cytokine Growth Factor Rev       Date:  2013-07-12       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.